Free Access
Med Sci (Paris)
Volume 22, Number 4, Avril 2006
Page(s) 416 - 422
Section M/S revues
Published online 15 April 2006
  1. Lotersztajn S. Les endothélines. Med Sci (Paris) 1993; 9 : 1084–93. [Google Scholar]
  2. Cazaubon S, Couraud PO. Nitric oxide and endothelin at the blood-brain barrier. In : Pardrige W, ed. Introduction to the blood-brain barrier. New York Raven Press Ltd, 1998 : 338–44. [Google Scholar]
  3. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2000; 11 : 1–6. [Google Scholar]
  4. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1 : 944–9. [Google Scholar]
  5. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis : emerging role in cancer. Nat Rev Cancer 2003; 3 : 110–6. [Google Scholar]
  6. Grant K, Loizidou M, Taylor I. Endothelin-1 : a multifunctional molecule in cancer. Br J Cancer 2003; 88 : 163–6. [Google Scholar]
  7. Deshayes F, Nahmias C. Angiotensin II receptors : a new role in cancer ? Trends Endocrinol Metab 2005; 16 : 293–9. [Google Scholar]
  8. Egidy G, Baviera E, Ciuffo G, et al. Localization of the endothelin system in aldosterone-producing adenomas. Hypertension 2001; 38 : 1137–42. [Google Scholar]
  9. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004; 90 : 1059–68. [Google Scholar]
  10. Anguelova E, Beuvon F, Leonard N, et al. Functional endothelin ET(B) receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 2005; 137 : 77–88. [Google Scholar]
  11. Lazarini F, Strosberg AD, Couraud PO, Cazaubon SM. Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. J Neurochem 1996; 66 : 459–65. [Google Scholar]
  12. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999; 96 : 11496–500. [Google Scholar]
  13. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001; 89 : 1138–46. [Google Scholar]
  14. Boivin B, Chevalier D, Villeneuve LR, et al. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003; 278 : 29153–63. [Google Scholar]
  15. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112 : 67–75. [Google Scholar]
  16. Fujita M, Hayashi I, Yamashina S, et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26 : 271–9. [Google Scholar]
  17. Arrieta O, Guevara P, Escobar E, et al. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005; 92 : 1247–52. [Google Scholar]
  18. Fischer O, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003; 31 : 1203–8. [Google Scholar]
  19. Elbaz N, Bedecs K, Masson M, et al. Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. Mol Endocrinol 2000; 14 : 795–804. [Google Scholar]
  20. Nouet S, Amzallag N, Li J, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004; 279 : 28989–97. [Google Scholar]
  21. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003; 14 : 44–50. [Google Scholar]
  22. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator : biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2 : 385–99. [Google Scholar]
  23. Rosano L, Spinella F, Di Castro V, et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi’s sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003; 163 : 753–62. [Google Scholar]
  24. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100 : 10954–9. [Google Scholar]
  25. Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000; 83 : 360–5. [Google Scholar]
  26. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98 : 671–9. [Google Scholar]
  27. Prontera C, Mariani B, Rossi C, et al. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81 : 761–6. [Google Scholar]
  28. Lindberg H, Nielsen D, Jensen B, et al. Angiotensin converting enzyme inhibitors for cancer treatment ? Acta Oncol 2004; 43 : 142–52. [Google Scholar]
  29. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62 : 4176–9. [Google Scholar]
  30. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294 : 441–7. [Google Scholar]
  31. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11 : 2686–94. [Google Scholar]
  32. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer : a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21 : 679–89. [Google Scholar]
  33. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas : safety and pharmacokinetics. J Clin Oncol 2002; 20 : 2171–80. [Google Scholar]
  34. Lever A, Hole D, Gillis C, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer ? Lancet 1998; 352 : 179–84. [Google Scholar]
  35. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer : a population-based cohort study in Denmark. Cancer 2001; 92 : 2462–70. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.